This study looks at how well sacituzumab tirumotecan (also called sac-TMT) works with pembrolizumab in treating advanced or recurrent endometrial cancer. Endometrial cancer starts in the lining of the uterus. The main goal is to find out if the combination helps people live longer and keeps their cancer from getting worse compared to pembrolizumab alone.
The trial's ID number is NCT06952504. This is a Phase 3 trial, meaning it is looking at how well the treatment works and how safe it is. It is regulated by the FDA, and the study aims to include about 1,123 participants.
Who can join
Women aged 18 and older with advanced or recurrent endometrial cancer that has certain proteins (known as proficient mismatch repair) can join. They should not have certain other types of cancer or have received specific prior treatments. The trial team will confirm eligibility for each person.
Condition
Endometrial Cancer
Age group
Adult, Older adult
Sex
Female
The study team makes the final call on eligibility.
What happens in the study
Participants will first receive a combination of pembrolizumab, carboplatin, and either paclitaxel or docetaxel for six cycles. After this, those whose cancer does not progress will be randomly assigned to either receive sac-TMT with pembrolizumab or pembrolizumab alone for maintenance treatment. If the cancer does progress, participants can enter another phase with different treatment options.
Where
This trial is enrolling at 44 locations. Recruiting sites are listed first.
AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)
Treats cervical cancer, uterine cancer, ovarian cancer and vulvar cancer. Offers laparoscopic surgery, fertility-sparing surgery and prophylactic surgery.
Chief of gynecologic medical oncology, MSK. Treats cervical cancer, uterine cancer and ovarian cancer. Offers chemotherapy. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.